Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K

Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the European Patent Office has issued an intention to grant communication for EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The application covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.

The intention to grant is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until 2032.

”It is gratifying to see how we continue to build a stronger patent protection for T20K in Europe with the announcement that the EPO intends to grant our divisional patent. Patent protection strengthens the project and increases the value for us as a company. Patent protection is very important for the future commercialization of T20K and especially in strategic markets such as the European market.”, says Carl-Magnus Högerkorp, CEO at Cyxone.

Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com

About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com